Stryker Corporation to Post Q1 2018 Earnings of $1.60 Per Share, Oppenheimer Forecasts (NYSE:SYK)

Stryker Corporation (NYSE:SYK) – Equities research analysts at Oppenheimer issued their Q1 2018 earnings per share estimates for shares of Stryker in a research note issued on Thursday, according to Zacks Investment Research. Oppenheimer analyst S. Lichtman forecasts that the medical technology company will post earnings of $1.60 per share for the quarter. Oppenheimer has a “Hold” rating and a $165.00 price objective on the stock. Oppenheimer also issued estimates for Stryker’s Q2 2018 earnings at $1.73 EPS, Q3 2018 earnings at $1.65 EPS, Q4 2018 earnings at $2.13 EPS and FY2019 earnings at $7.80 EPS.

A number of other equities analysts have also recently commented on SYK. Zacks Investment Research cut Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Robert W. Baird reiterated a “hold” rating and set a $161.00 price target on shares of Stryker in a report on Friday, October 27th. Piper Jaffray Companies reiterated a “buy” rating and set a $156.00 price target on shares of Stryker in a report on Friday, October 27th. Wells Fargo & Co lifted their price target on Stryker from $160.00 to $166.00 in a report on Friday, October 27th. Finally, Stifel Nicolaus lifted their price target on Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. Stryker currently has an average rating of “Hold” and a consensus target price of $162.50.

Stryker (SYK) traded up $3.21 during trading on Friday, reaching $151.22. The company had a trading volume of 1,544,943 shares, compared to its average volume of 1,519,259. Stryker has a fifty-two week low of $122.28 and a fifty-two week high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The company has a market capitalization of $56,653.36, a PE ratio of 56.43, a P/E/G ratio of 2.17 and a beta of 0.70.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.55% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the business posted $1.78 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.24%. Stryker’s payout ratio is 70.15%.

In other news, VP William E. Berry, Jr. sold 1,306 shares of Stryker stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Howard E. Cox, Jr. sold 7,400 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,840 shares of company stock valued at $2,749,989. 7.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in SYK. Koch Industries Inc. raised its position in Stryker by 34,120.3% during the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock valued at $1,252,000 after purchasing an additional 1,256,991 shares in the last quarter. BlackRock Inc. raised its position in Stryker by 5.2% during the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock valued at $3,208,017,000 after purchasing an additional 1,139,082 shares in the last quarter. Janus Henderson Group PLC raised its position in Stryker by 2,237.8% during the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock valued at $141,452,000 after purchasing an additional 975,656 shares in the last quarter. Vanguard Group Inc. raised its position in Stryker by 2.8% during the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock valued at $3,341,643,000 after purchasing an additional 657,656 shares in the last quarter. Finally, APG Asset Management N.V. raised its position in Stryker by 117.1% during the third quarter. APG Asset Management N.V. now owns 583,736 shares of the medical technology company’s stock valued at $82,902,000 after purchasing an additional 314,800 shares in the last quarter. Institutional investors and hedge funds own 74.85% of the company’s stock.

WARNING: “Stryker Corporation to Post Q1 2018 Earnings of $1.60 Per Share, Oppenheimer Forecasts (NYSE:SYK)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/11/stryker-corporation-expected-to-post-q1-2018-earnings-of-1-60-per-share-syk.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply